Review




Structured Review

Applied Viromics LLC prep-cap1 aav helper plasmid
Prep Cap1 Aav Helper Plasmid, supplied by Applied Viromics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prep-cap1+aav+helper+plasmid/prep+cap3+aav+helper+plasmid/us10415020-254-55-61
Average 90 stars, based on 1 article reviews
prep-cap1 aav helper plasmid - by Bioz Stars, 2026-11
90/100 stars

Images

Related Articles

Transfection:

Article Title: Method for producing non-enveloped viral particles
Article Snippet: (1) Seeding of Cell for Production of rAAV Cells for production of rAAV were seeded in the same manner as Example 1-(1). (2) Transfection of Plasmid for Production of rAAV The cells obtained by Example 3-(1) were transfected with a plasmid for production of rAAV in the same manner as Example 1-(2), except that a pRep-Cap1 AAV helper plasmid (manufactured by Applied Viromics), a pRC2-mi342 vector (manufactured by TAKARA BIO INC.), a pRep-Cap3 AAV helper plasmid (manufactured by Applied Viromics), or a pRC6 vector (manufactured by TAKARA BIC INC.) was used instead of the pRC5 vector according to the serotype of rAAV to be prepared. (3) Preparation of Extract by Citrate Buffer Treatment An extract of rAAV of each serotype was prepared in the same manner as Example 1-(3). (4) Formation and Removal of Precipitate by Addition of Sodium Deoxycholate and Addition of Citric Acid To the extract obtained by Example 3-(3), 1/100 volume of 20 U/μL Cryonase (registered trademark) Cold-active Nuclease (manufactured by TAKARA BIO INC.) was added (final concentration: 0.2 U/μL), and then reacted at 37° C. for 1 hour.

Plasmid Preparation:

Article Title: Method for producing non-enveloped viral particles
Article Snippet: (1) Seeding of Cell for Production of rAAV Cells for production of rAAV were seeded in the same manner as Example 1-(1). (2) Transfection of Plasmid for Production of rAAV The cells obtained by Example 3-(1) were transfected with a plasmid for production of rAAV in the same manner as Example 1-(2), except that a pRep-Cap1 AAV helper plasmid (manufactured by Applied Viromics), a pRC2-mi342 vector (manufactured by TAKARA BIO INC.), a pRep-Cap3 AAV helper plasmid (manufactured by Applied Viromics), or a pRC6 vector (manufactured by TAKARA BIC INC.) was used instead of the pRC5 vector according to the serotype of rAAV to be prepared. (3) Preparation of Extract by Citrate Buffer Treatment An extract of rAAV of each serotype was prepared in the same manner as Example 1-(3). (4) Formation and Removal of Precipitate by Addition of Sodium Deoxycholate and Addition of Citric Acid To the extract obtained by Example 3-(3), 1/100 volume of 20 U/μL Cryonase (registered trademark) Cold-active Nuclease (manufactured by TAKARA BIO INC.) was added (final concentration: 0.2 U/μL), and then reacted at 37° C. for 1 hour.

Bioprocessing:

Article Title: Method for producing non-enveloped viral particles
Article Snippet: (1) Seeding of Cell for Production of rAAV Cells for production of rAAV were seeded in the same manner as Example 1-(1). (2) Transfection of Plasmid for Production of rAAV The cells obtained by Example 3-(1) were transfected with a plasmid for production of rAAV in the same manner as Example 1-(2), except that a pRep-Cap1 AAV helper plasmid (manufactured by Applied Viromics), a pRC2-mi342 vector (manufactured by TAKARA BIO INC.), a pRep-Cap3 AAV helper plasmid (manufactured by Applied Viromics), or a pRC6 vector (manufactured by TAKARA BIC INC.) was used instead of the pRC5 vector according to the serotype of rAAV to be prepared. (3) Preparation of Extract by Citrate Buffer Treatment An extract of rAAV of each serotype was prepared in the same manner as Example 1-(3). (4) Formation and Removal of Precipitate by Addition of Sodium Deoxycholate and Addition of Citric Acid To the extract obtained by Example 3-(3), 1/100 volume of 20 U/μL Cryonase (registered trademark) Cold-active Nuclease (manufactured by TAKARA BIO INC.) was added (final concentration: 0.2 U/μL), and then reacted at 37° C. for 1 hour.

Concentration Assay:

Article Title: Method for producing non-enveloped viral particles
Article Snippet: (1) Seeding of Cell for Production of rAAV Cells for production of rAAV were seeded in the same manner as Example 1-(1). (2) Transfection of Plasmid for Production of rAAV The cells obtained by Example 3-(1) were transfected with a plasmid for production of rAAV in the same manner as Example 1-(2), except that a pRep-Cap1 AAV helper plasmid (manufactured by Applied Viromics), a pRC2-mi342 vector (manufactured by TAKARA BIO INC.), a pRep-Cap3 AAV helper plasmid (manufactured by Applied Viromics), or a pRC6 vector (manufactured by TAKARA BIC INC.) was used instead of the pRC5 vector according to the serotype of rAAV to be prepared. (3) Preparation of Extract by Citrate Buffer Treatment An extract of rAAV of each serotype was prepared in the same manner as Example 1-(3). (4) Formation and Removal of Precipitate by Addition of Sodium Deoxycholate and Addition of Citric Acid To the extract obtained by Example 3-(3), 1/100 volume of 20 U/μL Cryonase (registered trademark) Cold-active Nuclease (manufactured by TAKARA BIO INC.) was added (final concentration: 0.2 U/μL), and then reacted at 37° C. for 1 hour.



Similar Products

90
Applied Viromics LLC prep-cap1 aav helper plasmid
Prep Cap1 Aav Helper Plasmid, supplied by Applied Viromics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prep-cap1+aav+helper+plasmid/prep+cap3+aav+helper+plasmid/us10415020-254-55-61
Average 90 stars, based on 1 article reviews
prep-cap1 aav helper plasmid - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results